Tokyo Tape
Sign in
← OncoTherapy Science

Half-year report · HY

4564.TEDINET S100X054
Period2025-04-01 → 2025-09-30
Filed2025-11-10
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 42
MetricValuePeriodScopeSource row
Revenue¥432m2025-04-01 → 2025-09-30Cons.Net sales
Revenue¥225m2024-04-01 → 2024-09-30Cons.Net sales
Operating income−¥476m2025-04-01 → 2025-09-30Cons.Operating income
Operating income−¥531m2024-04-01 → 2024-09-30Cons.Operating income
Ordinary income−¥494m2025-04-01 → 2025-09-30Cons.Ordinary income
Ordinary income−¥815m2024-04-01 → 2025-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income−¥545m2024-04-01 → 2024-09-30Cons.Ordinary income
Profit before tax−¥554m2025-04-01 → 2025-09-30Cons.Income before income taxes
Profit before tax−¥545m2024-04-01 → 2024-09-30Cons.Income before income taxes
Net income (owners)−¥555m2025-04-01 → 2025-09-30Cons.Profit loss attributable to owners of parent
Net income (owners)−¥815m2024-04-01 → 2025-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)−¥546m2024-04-01 → 2024-09-30Cons.Profit loss attributable to owners of parent
Net income−¥555m2025-04-01 → 2025-09-30Cons.Profit loss
Net income−¥546m2024-04-01 → 2024-09-30Cons.Profit loss
Total assets¥1.9bnat 2025-09-30Cons.Assets
Total assets¥1.2bnat 2025-03-31Cons.Assets
Total assets¥1.5bnat 2024-09-30Cons.Total assets (5-year summary)
Total liabilities¥289mat 2025-09-30Cons.Liabilities
Total liabilities¥426mat 2025-03-31Cons.Liabilities
Net assets / equity¥1.6bnat 2025-09-30Cons.Net assets
Net assets / equity¥729mat 2025-03-31Cons.Net assets
Net assets / equity¥1.0bnat 2024-09-30Cons.Net assets (5-year summary)
Cash and deposits¥1.7bnat 2025-09-30Cons.Cash and deposits
Cash and deposits¥834mat 2025-03-31Cons.Cash and deposits
Cash & equivalents¥1.7bnat 2025-09-30Cons.Cash and cash equivalents
Cash & equivalents¥834mat 2025-03-31Cons.Cash and cash equivalents
Cash & equivalents¥1.1bnat 2024-09-30Cons.Cash and cash equivalents
Cash & equivalents¥528mat 2024-03-31vCons.Cash and cash equivalents
Operating cash flow−¥525m2025-04-01 → 2025-09-30Cons.Net cash provided by used in operating activities
Operating cash flow−¥815m2024-04-01 → 2025-03-31Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow−¥579m2024-04-01 → 2024-09-30Cons.Net cash provided by used in operating activities
Investing cash flow−¥61m2025-04-01 → 2025-09-30Cons.Net cash provided by used in investment activities
Investing cash flow−¥279,0002024-04-01 → 2025-03-31Cons.Net cash provided by used in investing activities (5-year summary)
Financing cash flow¥1.4bn2025-04-01 → 2025-09-30Cons.Net cash provided by used in financing activities
Financing cash flow¥1.1bn2024-04-01 → 2025-03-31Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow¥1.1bn2024-04-01 → 2024-09-30Cons.Net cash provided by used in financing activities
EPS (basic)¥-1.892025-04-01 → 2025-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-3.122024-04-01 → 2025-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-2.182024-04-01 → 2024-09-30Cons.Basic earnings loss per share (5-year summary)
Equity ratio81.4%at 2025-09-30Cons.Equity to asset ratio (5-year summary)
Equity ratio57.0%at 2025-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio59.9%at 2024-09-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 28
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2025-04-01 → 2025-09-30−¥185,000
Reconciling Itemsreconcilingrevenue intersegment2025-04-01 → 2025-09-30−¥185,000
Reconciling Itemsreconcilingsegment profit2025-04-01 → 2025-09-30−¥185m
Cancer Precision Medical Businessreportable segmentrevenue2025-04-01 → 2025-09-30¥430m
Cancer Precision Medical Businessreportable segmentrevenue external2025-04-01 → 2025-09-30¥430m
Cancer Precision Medical Businessreportable segmentsegment profit2025-04-01 → 2025-09-30−¥7m
Research And Development Of Pharmaceutical Productsreportable segmentrevenue2025-04-01 → 2025-09-30¥3m
Research And Development Of Pharmaceutical Productsreportable segmentrevenue external2025-04-01 → 2025-09-30¥2m
Research And Development Of Pharmaceutical Productsreportable segmentrevenue intersegment2025-04-01 → 2025-09-30¥185,000
Research And Development Of Pharmaceutical Productsreportable segmentsegment profit2025-04-01 → 2025-09-30−¥284m
—segment totalrevenue2025-04-01 → 2025-09-30¥432m
—segment totalrevenue external2025-04-01 → 2025-09-30¥432m
—segment totalrevenue intersegment2025-04-01 → 2025-09-30¥185,000
—segment totalsegment profit2025-04-01 → 2025-09-30−¥291m
Reconciling Itemsreconcilingrevenue2024-04-01 → 2024-09-30−¥135,000
Reconciling Itemsreconcilingrevenue intersegment2024-04-01 → 2024-09-30−¥135,000
Reconciling Itemsreconcilingsegment profit2024-04-01 → 2024-09-30−¥178m
Cancer Precision Medical Businessreportable segmentrevenue2024-04-01 → 2024-09-30¥222m
Cancer Precision Medical Businessreportable segmentrevenue external2024-04-01 → 2024-09-30¥222m
Cancer Precision Medical Businessreportable segmentsegment profit2024-04-01 → 2024-09-30−¥94m
Research And Development Of Pharmaceutical Productsreportable segmentrevenue2024-04-01 → 2024-09-30¥3m
Research And Development Of Pharmaceutical Productsreportable segmentrevenue external2024-04-01 → 2024-09-30¥3m
Research And Development Of Pharmaceutical Productsreportable segmentrevenue intersegment2024-04-01 → 2024-09-30¥135,000
Research And Development Of Pharmaceutical Productsreportable segmentsegment profit2024-04-01 → 2024-09-30−¥259m
—segment totalrevenue2024-04-01 → 2024-09-30¥225m
—segment totalrevenue external2024-04-01 → 2024-09-30¥225m
—segment totalrevenue intersegment2024-04-01 → 2024-09-30¥135,000
—segment totalsegment profit2024-04-01 → 2024-09-30−¥353m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 400
ItemContextValueUnit
Business expensesPrior1InterimDuration756201000JPY
Business expensesInterimDuration907830000JPY
Operating incomePrior1InterimDuration-531117000JPY
Operating incomeInterimDuration-475938000JPY
Foreign exchange gains noiPrior1InterimDuration1834000JPY
Foreign exchange gains noiInterimDuration396000JPY
Other noiPrior1InterimDuration389000JPY
Other noiInterimDuration－JPY
Non operating incomePrior1InterimDuration2224000JPY
Non operating incomeInterimDuration396000JPY
Interest expenses noePrior1InterimDuration546000JPY
Interest expenses noeInterimDuration655000JPY
Stock issuance cost noePrior1InterimDuration15729000JPY
Stock issuance cost noeInterimDuration17436000JPY
Non operating expensesPrior1InterimDuration16276000JPY
Non operating expensesInterimDuration18091000JPY
Ordinary incomePrior1InterimDuration-545169000JPY
Ordinary incomeInterimDuration-493633000JPY
Gain on reversal of subscription rights to shares eiPrior1InterimDuration550000JPY
Gain on reversal of subscription rights to shares eiInterimDuration550000JPY
Extraordinary incomePrior1InterimDuration550000JPY
Extraordinary incomeInterimDuration550000JPY
Impairment loss elPrior1InterimDuration－JPY
Impairment loss elInterimDuration60967000JPY
Extraordinary lossPrior1InterimDuration－JPY
Extraordinary lossInterimDuration60967000JPY
Income before income taxesPrior1InterimDuration-544619000JPY
Income before income taxesInterimDuration-554051000JPY
Income taxes currentPrior1InterimDuration1080000JPY
Income taxes currentInterimDuration1080000JPY
Income taxesPrior1InterimDuration1080000JPY
Income taxesInterimDuration1080000JPY
Profit lossPrior1InterimDuration-545699000JPY
Profit lossInterimDuration-555131000JPY
Profit loss attributable to owners of parentPrior1InterimDuration-545699000JPY
Profit loss attributable to owners of parentInterimDuration-555131000JPY
Profit lossPrior1InterimDuration-545699000JPY
Profit lossInterimDuration-555131000JPY
Comprehensive incomePrior1InterimDuration-545699000JPY
Comprehensive incomeInterimDuration-555131000JPY
Comprehensive income attributable to owners of the parentPrior1InterimDuration-545699000JPY
Comprehensive income attributable to owners of the parentInterimDuration-555131000JPY
Income before income taxesPrior1InterimDuration-544619000JPY
Income before income taxesInterimDuration-554051000JPY
Impairment loss ope cfPrior1InterimDuration－JPY
Impairment loss ope cfInterimDuration60967000JPY
Interest expenses ope cfPrior1InterimDuration546000JPY
Interest expenses ope cfInterimDuration655000JPY
Stock issuance cost ope cfPrior1InterimDuration15729000JPY
Stock issuance cost ope cfInterimDuration17436000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2025-03-31pass rounding
balance sheet identityconsolidated 2025-09-30pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2025-03-31pass
statement vs summary · net assetsconsolidated 2025-09-30pass
statement vs summary · net income attributable to parentconsolidated 2024-04-01/2024-09-30pass
statement vs summary · net income attributable to parentconsolidated 2025-04-01/2025-09-30pass
statement vs summary · operating cash flowconsolidated 2024-04-01/2024-09-30pass
statement vs summary · operating cash flowconsolidated 2025-04-01/2025-09-30pass
statement vs summary · total assetsconsolidated 2025-03-31pass
statement vs summary · total assetsconsolidated 2025-09-30pass